Objective:To systematically investigate the main active components,targets,target-related diseases and action mechanism of Yiyi Fuzi Baijiang powder(YFBP)of Zhang Zhongjing,a Chinese physician of Eastern Han Dynasty o...Objective:To systematically investigate the main active components,targets,target-related diseases and action mechanism of Yiyi Fuzi Baijiang powder(YFBP)of Zhang Zhongjing,a Chinese physician of Eastern Han Dynasty of China(3 century A.D.)using the method of network pharmacology.Methods:The active components of YFBP were identified from several databases(TCMSP,TCM Database@Taiwan and TCMID).The potential active compounds were screened based on oral bioavailability and drug-like index in the TCMSP database.DrugBank,TCMSP,and TCMID database searches were performed to predict target-related diseases.Biological functions and KEGG pathway outcomes of all potential targets were analyzed using the DAVID database.Results:A total of 24 active compounds of YFBP,133 related targets,and 305 potential related diseases were obtained.These results showed that YFBP may treat inflammation,pain,and cancer.The functional enrichment analysis indicated that YFBP probably exerts its therapeutic effects by regulating neuroactive ligand-receptor interactions,the TNF signaling pathway,and the PI3K-Akt signaling pathway.Conclusion:This study provides preliminary confirmation that YFBP has the great potentials to treat inflammation,pain,and tumors,which supports Zhang Zhongjing’s original intention to treat intestinal carbuncle with ancient prescription YFBP,but also provides a scientific basis for its treatment in the malignant tumors.展开更多
Objective:To explore the mechanism of Yiyi Fuzi Baijiang p owder in treatment of ulcerative colitis in Coix Lacryma-jobi based on network pharmacology and molecular docking technology.Methods:Search for Yiyi Fuzi Baij...Objective:To explore the mechanism of Yiyi Fuzi Baijiang p owder in treatment of ulcerative colitis in Coix Lacryma-jobi based on network pharmacology and molecular docking technology.Methods:Search for Yiyi Fuzi Baijiang powder’s active ingredient by traditional Chinese medicine database and analysis platform system pharmacology,Genecards,Uniprot database and Cytoscape software were used to construct the active component-ulcerative colitis disease target network,and gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis was performed,Autodock Vina was used for molecular docking verification.Results:Quercetin,luteolin,kaempferol,chrysin,macroanol B,β-sitosterol,stigmasterol,deltoan and rhizoctonine may play a role in the treatment of ulcerative colitis.KEGG pathway enrichment analysis showed that Yiyi Fuzi Baijiang p owder mainly involved i nterleukin-17 signaling pathway and cancer pathway,among which the key targets were PTGS2,HSP90AA1 and CASP3 and had a good binding activity with 10 main active components.Conclusion:The treatment of ulcerative colitis by Yiyi Fuzi Baijiang p owder may be mainly through quercetin,luteolin,macroanol B,β-sitosterol and other chemical components involved in cancer pathway,i nterleukin-17 signaling pathway acting on PTGS2,HSP90AA1,CASP3 and other disease targets in response to inorganic substances,response to cytokines and other biological processes f actor receptor binding and other molecular functions to achieve the purpose of treating u lcerative colitis.展开更多
OBJECTIVE:To observe the therapeutic effect of Wumei Baijiang prescription(乌梅败酱方),empirical prescription of Lu Zhizheng,on experimental ulcerative colitis(UC)mice,and to investigate the mechanism of the prescript...OBJECTIVE:To observe the therapeutic effect of Wumei Baijiang prescription(乌梅败酱方),empirical prescription of Lu Zhizheng,on experimental ulcerative colitis(UC)mice,and to investigate the mechanism of the prescription in UC from the perspective of the immune balance of regulatory T cells(Treg)and helper T cells(Th17).METHODS:Sixty C57 BL/6 mice were randomly divided into 6 groups:normal group,model group,Chinese medicine group(high,medium and low dose group of Wumei Baijiang prescription)and control group(mesalazine sustained-release granules).Except for the normal group,the other groups used 2.5%dextran sulfate sodium to induce UC mice model.At the end of the model,the Chinese medicine group was given high,medium and low dose administration of Wumei Baijiang prescription,the control group was given slow-release granules of mesalazine,and the model group was given equal volume saline for 10 d.The changes of food intake,body weight,disease activity index(DAI)score,length of large intestine and histopathology were observed.The number of Treg,Th17,CD4+,CD8+cells in spleen was detected by flow cytometry.The expression of tumor necrosis factor-α(TNF-α),interleukin-10(IL-10)and C-reactive protein(CRP)in serum was detected by enzyme-linked immunosorbent assay.RESULTS:The middle and high-dose groups of Wumei Baijiang prescription were superior to the model group in terms of increasing food intake and body weight of colitis mice,restoring colon morphology,improving pathological damage,and reducing DAI(P<0.05).There was no statistical difference with the mesalazine group(P>0.05).Compared with the model group,the spleen Treg and CD4+of the mice in the high and middle dose groups of Wumei Baijiang prescription were higher,while Th17 and CD8+were lower(P<0.05),and there was no statistical difference compared with the mesalazine group(P>0.05).In addition,compared with the model group,the serum levels of TNF-αand CRP in mice with high and middle doses of Wumei Baijiang prescription and mesalazine group were lower(P<0.05),and IL-10 content was higher(P<0.05).CONCLUSIONS:Wumei Baijiang prescription can improve the general conditions of colitis mice,such as diarrhea,hematochezia,weight loss,and mucosal damage.The mechanism may be related to the regulation of Treg/Th17 immune balance.展开更多
基金This research is supported by National Natural Science Foundation of China(81603434),Shanghai Natural Science Foundation Project(17ZR1438800)and Shanghai Health Planning Commission Project(ZY3-RCPY-1-1001,zybz-2017029).
文摘Objective:To systematically investigate the main active components,targets,target-related diseases and action mechanism of Yiyi Fuzi Baijiang powder(YFBP)of Zhang Zhongjing,a Chinese physician of Eastern Han Dynasty of China(3 century A.D.)using the method of network pharmacology.Methods:The active components of YFBP were identified from several databases(TCMSP,TCM Database@Taiwan and TCMID).The potential active compounds were screened based on oral bioavailability and drug-like index in the TCMSP database.DrugBank,TCMSP,and TCMID database searches were performed to predict target-related diseases.Biological functions and KEGG pathway outcomes of all potential targets were analyzed using the DAVID database.Results:A total of 24 active compounds of YFBP,133 related targets,and 305 potential related diseases were obtained.These results showed that YFBP may treat inflammation,pain,and cancer.The functional enrichment analysis indicated that YFBP probably exerts its therapeutic effects by regulating neuroactive ligand-receptor interactions,the TNF signaling pathway,and the PI3K-Akt signaling pathway.Conclusion:This study provides preliminary confirmation that YFBP has the great potentials to treat inflammation,pain,and tumors,which supports Zhang Zhongjing’s original intention to treat intestinal carbuncle with ancient prescription YFBP,but also provides a scientific basis for its treatment in the malignant tumors.
基金support plan of Shaanxi Province“Leading Talents in Scientific and Technological Innovation”program(TZ0326)Key Research and development projects of Shaanxi Province.
文摘Objective:To explore the mechanism of Yiyi Fuzi Baijiang p owder in treatment of ulcerative colitis in Coix Lacryma-jobi based on network pharmacology and molecular docking technology.Methods:Search for Yiyi Fuzi Baijiang powder’s active ingredient by traditional Chinese medicine database and analysis platform system pharmacology,Genecards,Uniprot database and Cytoscape software were used to construct the active component-ulcerative colitis disease target network,and gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis was performed,Autodock Vina was used for molecular docking verification.Results:Quercetin,luteolin,kaempferol,chrysin,macroanol B,β-sitosterol,stigmasterol,deltoan and rhizoctonine may play a role in the treatment of ulcerative colitis.KEGG pathway enrichment analysis showed that Yiyi Fuzi Baijiang p owder mainly involved i nterleukin-17 signaling pathway and cancer pathway,among which the key targets were PTGS2,HSP90AA1 and CASP3 and had a good binding activity with 10 main active components.Conclusion:The treatment of ulcerative colitis by Yiyi Fuzi Baijiang p owder may be mainly through quercetin,luteolin,macroanol B,β-sitosterol and other chemical components involved in cancer pathway,i nterleukin-17 signaling pathway acting on PTGS2,HSP90AA1,CASP3 and other disease targets in response to inorganic substances,response to cytokines and other biological processes f actor receptor binding and other molecular functions to achieve the purpose of treating u lcerative colitis.
基金Supported by Nation Science(Mechanism Study on Prevention and Relief Effects of Heat-clearing,Humidity-resolving and Pivot-regulating Methods on Model Mice Based on the Change of Intestinal Mucosal Barrier,No.81973638)Major National Disease-JiuLi(Ulcerative Colitis)Cooperation between Chinese and Western Medicine Pilot Project。
文摘OBJECTIVE:To observe the therapeutic effect of Wumei Baijiang prescription(乌梅败酱方),empirical prescription of Lu Zhizheng,on experimental ulcerative colitis(UC)mice,and to investigate the mechanism of the prescription in UC from the perspective of the immune balance of regulatory T cells(Treg)and helper T cells(Th17).METHODS:Sixty C57 BL/6 mice were randomly divided into 6 groups:normal group,model group,Chinese medicine group(high,medium and low dose group of Wumei Baijiang prescription)and control group(mesalazine sustained-release granules).Except for the normal group,the other groups used 2.5%dextran sulfate sodium to induce UC mice model.At the end of the model,the Chinese medicine group was given high,medium and low dose administration of Wumei Baijiang prescription,the control group was given slow-release granules of mesalazine,and the model group was given equal volume saline for 10 d.The changes of food intake,body weight,disease activity index(DAI)score,length of large intestine and histopathology were observed.The number of Treg,Th17,CD4+,CD8+cells in spleen was detected by flow cytometry.The expression of tumor necrosis factor-α(TNF-α),interleukin-10(IL-10)and C-reactive protein(CRP)in serum was detected by enzyme-linked immunosorbent assay.RESULTS:The middle and high-dose groups of Wumei Baijiang prescription were superior to the model group in terms of increasing food intake and body weight of colitis mice,restoring colon morphology,improving pathological damage,and reducing DAI(P<0.05).There was no statistical difference with the mesalazine group(P>0.05).Compared with the model group,the spleen Treg and CD4+of the mice in the high and middle dose groups of Wumei Baijiang prescription were higher,while Th17 and CD8+were lower(P<0.05),and there was no statistical difference compared with the mesalazine group(P>0.05).In addition,compared with the model group,the serum levels of TNF-αand CRP in mice with high and middle doses of Wumei Baijiang prescription and mesalazine group were lower(P<0.05),and IL-10 content was higher(P<0.05).CONCLUSIONS:Wumei Baijiang prescription can improve the general conditions of colitis mice,such as diarrhea,hematochezia,weight loss,and mucosal damage.The mechanism may be related to the regulation of Treg/Th17 immune balance.
